

# Current prospects for RNA interference-based therapies

Beverly L. Davidson<sup>\*†§</sup> and Paul B. McCray Jr<sup>\*||</sup>

**Abstract** | RNA interference (RNAi) is a powerful approach for reducing expression of endogenously expressed proteins. It is widely used for biological applications and is being harnessed to silence mRNAs encoding pathogenic proteins for therapy. Various methods — including delivering RNA oligonucleotides and expressing RNAi triggers from viral vectors — have been developed for successful RNAi in cell culture and *in vivo*. Recently, RNAi-based gene silencing approaches have been demonstrated in humans, and ongoing clinical trials hold promise for treating fatal disorders or providing alternatives to traditional small molecule therapies. Here we describe the broad range of approaches to achieve targeted gene silencing for therapy, discuss important considerations when developing RNAi triggers for use in humans, and review the current status of clinical trials.

RNA interference (RNAi) is a natural cellular process that regulates gene expression and provides an innate defence mechanism against invading viruses and transposable elements<sup>1</sup>. The finding that dsRNA initiates RNAi was among the most significant recent contributions to cell biology<sup>2</sup>, and since the discovery that RNAi can be mediated by 21 nucleotide (nt) duplexes<sup>3</sup>, researchers have worked to harness their potential for addressing biological questions and treating human disease. Some reagents, such as small interfering RNAs (siRNAs), are applied directly to cells, tissues and organisms; others are engineered to be expressed in cells, such as hairpin structures that provide siRNAs when processed. The basic premise underlying the broad utility of RNAi is that, in theory, we can design siRNAs (or vectors encoding them) to target virtually any gene of interest. RNAi technologies use a cell's natural machinery to move exogenously applied siRNAs to the appropriate cellular compartment, where they encounter the correct mRNA target and induce its degradation.

Initial work on RNAi in flies and worms moved quickly to larger mammals and fuelled excitement for potential clinical applications. However, in a similar way to other developing fields in human therapy, such as gene- and antibody-therapy, early excitement has been tempered as a realistic understanding emerges of the milestones that must be reached before the eventual approval of human therapy. Over recent years various complex barriers to achieving efficient RNAi have become evident. These hurdles include: specificity for the target gene; delivery to the correct cell or tissues; the

durability of RNAi activity and the ability to redose (if needed); and considerations of the stability of the target mRNA and encoded protein. We have also become aware of the problems posed by the various platforms used to elicit RNAi. However, with setbacks come opportunities. For example, early work in which siRNAs were applied to mouse airway epithelial cells to reduce viral burdens *in vivo* elicited inhibition of target gene expression<sup>4</sup>, but it was later found that the induction of an innate immune response probably contributed to the efficacy in these and other experiments<sup>5,6</sup>. Altering the chemical make-up of the synthetic RNA diminished the immune response, as did avoiding known pro-inflammatory sequences<sup>7,8</sup>. This finding also opened investigators' eyes to the possibility of purposefully using immunostimulatory RNAi as a direct therapeutic or adjuvant<sup>9</sup>.

Although the clinical utility of RNAi has not yet been realized, ongoing patient trials provide opportunities for success. The numbers of RNAi-based preclinical and clinical trials have grown over the past several years and have included studies in retinal degeneration, dominantly inherited brain and skin diseases, viral infections, respiratory disorders, cancer and metabolic diseases (TABLE 1).

Here, we provide an overview of RNAi and discuss strategies to use the pathway for directed gene silencing for therapy. We describe delivery systems that might be suitable for different circumstances, and bring to the reader's attention issues that must be surmounted for widespread use *in vivo*.

Departments of <sup>\*</sup>Internal Medicine, <sup>†</sup>Neurology, <sup>§</sup>Physiology & Biophysics and <sup>||</sup>Pediatrics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.  
Correspondence to B.L.D.  
e-mail: [beverly-davidson@uiowa.edu](mailto:beverly-davidson@uiowa.edu)  
doi:10.1038/nrg2968

Table 1 | Clinical trials for RNAi therapy\*

Clinical setting	Drug	Indication(s)	Target(s)	Sponsor	Status
Ocular and retinal disorders	TD101	Pachyonychia congenita	Keratin 6A N171K mutant	Pachyonychia Congenita Project	Completed, Phase I
	QPI-1007	Non-arteritic anterior ischaemic optic neuropathy	Caspase 2	Quark Pharm., Inc.	Active, Phase I
	AGN211745	Age-related macular degeneration; choroidal neovascularization	VEGFR1	Sirna Therapeutics, Inc.	Completed, Phase I, II
	PF-655	Diabetic macular oedema (DME); age-related macular degeneration (AMD)	RTP801	Quark Pharm., Inc.	Active, Phase I
	SYL040012	Glaucoma	$\beta$ 2 adrenergic receptor	Sylentis	Active, Phase I, II
	Bevasiranib	Diabetic macular oedema	VEGF	Opko Health, Inc.	Completed, Phase II
	Bevasiranib	Macular degeneration	VEGF	Opko Health, Inc.	Completed, Phase II
Cancer	CEQ508	Familial adenomatous polyposis	$\beta$ -catenin	MDRNA, Inc.	Active, Phase I
	ALN-PLK1	Liver tumours	PLK1	Alnyam Pharm.	Active, Phase I
	FANG	Solid tumours	Furin	Gradalis, Inc.	Active, Phase II
	CALAA-01	Solid tumours	RRM2	Calando Pharm.	Active, Phase I
	SPC2996	Chronic myeloid leukemia	BCL-2	Santaris Pharm.	Ongoing, Phase I, II
	ALN-VSP02	Solid tumours	VEGF, kinesin spindle protein	Alnylam Pharm.	Active, Phase I
	NCT00672542	Metastatic melanoma	LMP2, LMP7, and MECL1	Duke University	Active, Phase I
	Atu027	Advanced, recurrent or metastatic solid malignancies	PKN3	Silence Therapeutics	Active, Phase I
Kidney disorders	QPI-1002/I5NP	Acute kidney injury	p53	Quark Pharm., Inc.	Terminated, Phase I
	QPI-1002/I5NP	Delayed graft function kidney transplant	p53	Quark Pharm., Inc.	Active, Phase I, II
	QPI-1002/I5NP	Kidney injury acute renal failure	p53	Quark Pharm., Inc.	Completed, Phase I
LDL lowering	TKM-ApoB	Hypercholesterolaemia	APOB	Tekmira Pharm. Corp.	Terminated, Phase I
	PRO-040,201	Hypercholesterolaemia	APOB	Tekmira Pharm. Corp.	Terminated, Phase I
Antiviral	SPC3649	Hepatitis C virus	miR-122	Santaris Pharm	Active, Phase II
	pHIV7-shI-TAR-CCR5RZ	HIV	HIV Tat protein, HIV TAR RNA, human CCR5	City of Hope Medical Center/Benitec	Active, Phase 0
	ALN-RSV01	RSV in volunteers	RSV nucleocapsid	Alnylam Pharm.	Completed, Phase II
	ALN-RSV01	RSV in lung transplant patients	RSV nucleocapsid	Alnylam Pharm.	Completed, Phase I
	ALN-RSV01	RSV in lung transplant patients	RSV nucleocapsid	Alnylam Pharm.	Active, Phase II

APOB, apolipoprotein B; BCL-2, B-cell CLL/lymphoma 2; CCR5, C-C chemokine receptor type 5; LDL, low-density lipoprotein; LMP2, also known as proteasome subunit beta type 9 (PSMB9); LMP7, also known as proteasome subunit beta type 8 (PSMB8); MECL1, also known as proteasome subunit beta type 10 (PSMB10); Pharm., Pharmaceuticals; PKN3, protein kinase N3; PLK1, polo-like kinase 1; RRM2, ribonucleoside-diphosphate reductase subunit M2; RSV, respiratory syncytial virus; RTP801, also known as DNA damage-inducible transcript 4 protein (DDIT4); VEGF, vascular endothelial growth factor. \*From [ClinicalTrials.gov](http://ClinicalTrials.gov).


### Harnessing small RNA biogenesis

The development of RNAi for therapy is based on our understanding of small RNA biogenesis pathways. The two main types of small RNAs involved in gene silencing are microRNAs (miRNAs) and siRNAs, and their processing and targeting is summarized in FIG. 1 (further details can be found in recent reviews<sup>10–12</sup>).

**miRNAs and siRNAs.** miRNAs mediate post-transcriptional gene silencing and are processed from endogenously expressed transcripts (FIG. 1). Either processed strand can mediate post-transcriptional gene silencing, but many miRNAs show asymmetry, primarily loading one strand into the RNA-induced silencing complex (RISC). The small

RNA guides RISC to the mRNA target, where the miRNA typically binds to the 3' UTR. Watson–Crick base pairing between miRNAs and their targets is usually partial, but with high complementarity from bases 2–8 of the miRNA, which is known as the 'seed' region<sup>13</sup>. Recent data suggest that base pairing can also occur between central miRNA nucleotides and target mRNAs<sup>14</sup>. Data from several laboratories showed that miRNAs repress the initiation of translation<sup>15–17</sup>, although more recent work indicates that miRNA–mRNA complexes can be transported to cytoplasmic processing bodies<sup>18</sup>, after which deadenylation and mRNA degradation occurs<sup>14,19,20</sup>. Interestingly, some miRNA-mediated translational repression is reversible<sup>21</sup>.

**RNA-induced silencing complex (RISC).** RISC is a group of proteins, including one of the Argonaute proteins, that induces target mRNA cleavage based on loaded small interfering RNA or microRNA guide strands.



**Figure 1 | The miRNA and siRNA pathways of RNAi in mammals.** Primary microRNAs (pri-miRNAs) are transcribed by RNA polymerases<sup>156–158</sup> and are trimmed by the microprocessor complex (comprising Drosha and microprocessor complex subunit DGCR8) into ~70 nucleotide precursors, called pre-miRNAs<sup>67,159,160</sup> (left side of the figure). miRNAs can also be processed from spliced short introns (known as mirtrons)<sup>161</sup>. pre-miRNAs contain a loop and usually have interspersed mismatches along the duplex. pre-miRNAs associate with exportin 5 and are exported to the cytoplasm<sup>162,163</sup>, where a complex that contains Dicer, TAR RNA-binding protein (TRBP; also known as TARBP2) and PACT (also known as PRKRA) processes the pre-miRNAs into miRNA-miRNA\* duplexes<sup>116,164,165</sup>. The duplex associates with an Argonaute (AGO) protein within the precursor RNAi-induced silencing complex (pre-RISC). One strand of the duplex (the passenger strand) is removed. The mature RISC contains the guide strand, which directs the complex to the target mRNA for post-transcriptional gene silencing. The 'seed' region of an miRNA is indicated; in RNAi trigger design, the off-target potential of this sequence needs to be considered. Long dsRNAs (right side of the figure) are processed by Dicer, TRBP and PACT into small interfering RNAs (siRNAs). siRNAs are 20–24-mer RNAs and harbour 3'OH and 5' phosphate (PO<sub>4</sub>) groups, with 3' dinucleotide overhangs<sup>3,166,167</sup>. Within the pre-RISC complex, an AGO protein cleaves the passenger siRNA strand. Then, the mature RISC, containing an AGO protein and the guide strand, associates with the target mRNA for cleavage. The inset shows the properties of siRNAs. The thermodynamic stability of the terminal sequences will direct strand loading. Like naturally occurring or artificially engineered miRNAs, the potential 'seed' region can be a source for miRNA-like off-target silencing. shRNA, short hairpin RNA.

**Seed**

A sequence of seven bases in a microRNA that is complementary to the mRNA target. This sequence is essential for the initial binding of the microRNA to most targets. Seeds can also exist arbitrarily in small interfering RNAs and processed short hairpin RNAs, causing microRNA-like silencing.

**Primary miRNAs**

(pri-miRNAs). The initial transcriptional products of microRNA genes. They are generally >100 nucleotides long and may contain one or more microRNA stem loops that are processed by the microRNA biogenesis pathway.

**Precursor miRNAs**

(pre-miRNAs). Hairpin precursors of microRNAs formed by the cleavage of primary microRNAs by DCGR8 and Drosha.

**Dicer**

A member of the RNase III family of ribonucleases that cleaves dsRNAs into small interfering RNAs, and precursor microRNAs and mirtrons into microRNAs.

**Type I interferon response**

An innate immune response to dsRNA, ssRNA, CpG DNA and other stimuli that triggers a protective antiviral response in host cells. Signalling elicits  $\alpha$ - and  $\beta$ -interferon release, which activate multiple components of innate and adaptive immunity.

**Toll-like receptors**

(TLRs). A family of receptors that recognize pathogen-associated molecular patterns (PAMPs), including some DNA and RNA molecules.

**CpG oligonucleotides**

Immunostimulatory dinucleotide motifs that interact with Toll-like receptor 9.

**Stable nucleic acid lipid particle**

(SNALP). A lipid nanoparticle formulation for the systemic delivery of small interfering RNAs to tissues.

siRNAs are small dsRNAs, 20–24 nt in length, that are processed from longer dsRNAs (FIG. 1). One strand is the ‘guide’ strand and directs silencing, with the other strand — the ‘passenger’ — being degraded<sup>22,23</sup>. Which strand becomes which is determined by the thermodynamic properties of the duplex<sup>24–27</sup>. siRNAs generally show full complementarity to their target mRNA, and cleavage occurs 10–12 bases from the 5’ end of the guide strand binding site<sup>3,28</sup>.

**Exogenous inhibitory RNAs.** Our understanding of small RNA biogenesis has enabled the development of several strategies for harnessing RNAi pathways for therapy. Recombinant inhibitory RNAs are designed to mimic primary miRNAs (pri-miRNAs) (in the case of artificial miRNAs or exogenous miRNAs) or precursor miRNAs (pre-miRNAs) (in the case of short hairpin RNAs (shRNAs)), whereas chemically synthesized RNA oligonucleotides are designed to mimic Dicer products or substrates. Each class mediates gene silencing but enters the pathway at a different step (FIG. 1). The main differences between exogenously applied oligonucleotide siRNAs and hairpin-based species (shRNA or miRNA shuttles) are the mode of delivery and the duration of gene silencing (TABLE 2). However, recent advances in non-viral and viral systems are blurring this distinction. In the following sections we describe the main strategies for the design and delivery of inhibitory RNAs.

**siRNA approaches**

The most common method used to harness the RNAi pathway for targeted gene silencing is to transfect 21–22 nt siRNAs into cells. Another option is to use longer, 25–27 nt duplexes that can be processed by Dicer into siRNAs; these are called ‘Dicer-ready siRNAs’. In some cases, the silencing potency of Dicer-ready siRNAs can be greater than for siRNAs<sup>29,30</sup>. For both synthetic triggers, transfection is generally accomplished to high efficiency in cell lines using commercially available transfection reagents. However, as discussed below, alternative packaging is often required for delivery to primary cells and for *in vivo* applications.

In rational siRNA design it is important to consider the siRNA sequence, the chemical nature of the silencing moiety (for example, RNA with or without modified bases and sugars), the length of the RNA and the nature of the 5’ and 3’ ends. *In vitro* synthesis of siRNAs using T7 polymerase creates 5’ triphosphates, which can induce type I interferon responses (type I IFN responses)<sup>1</sup>. Similarly, blunt-ended siRNAs induce cytoplasmic retinoic acid inducible gene 1 protein (RIG1; also known as DDX58) and IFN production. Chemically synthesized siRNAs lacking 5’ triphosphates and containing appropriate 3’ overhangs alleviate these issues.

Many siRNAs, although able to reduce expression of the target gene, are immunostimulatory in a sequence-independent manner because they are recognized by the pattern recognition Toll-like receptors (TLRs)<sup>31</sup>. TLR3, which can be endosomal or on the cell surface, recognizes dsRNAs and can be activated by uncomplexed 21-mer siRNAs. TLR3 activation inhibits blood and

lymphatic vessel growth<sup>32,33</sup>, which can be advantageous in the setting of corneal vascularization, where inhibition of angiogenesis is desired<sup>34</sup>. TLR activation can also be advantageous in cancer therapies by stimulating dendritic cells to respond immunologically to cancer cells<sup>35</sup>. Recently, the generally unwanted stimulation of TLRs by oligonucleotides was used cleverly to achieve gene silencing and immune stimulation for cancer therapy: well-characterized CpG oligonucleotide agonists of TLR9 fused to siRNAs targeting an immune suppressor promoted antitumour immune responses in mice<sup>36</sup>. This interesting combination of tumour targeting and siRNA immunostimulatory therapy may substantially augment the promising clinical results from the use of TLR9 agonists alone<sup>37</sup>.

TLR activation would be contraindicated in other settings, such as in attempts to revert or inhibit ischaemia. In addition, endosomal TLR7 and TLR8 recognize ssRNAs and can be activated when siRNAs complexed with carriers are internalized or taken up through receptor targeting. Altering the chemical nature of the siRNA dramatically reduces TLR responses elicited by exogenously applied siRNAs. For example, using 2’-O-methyl-modified purine nucleosides in the passenger strand reduces IFN induction but retains targeting specificity<sup>38–40</sup>. This modification also improves serum stability by reducing susceptibility to RNases<sup>41</sup>.

**siRNA delivery options.** Chemically modified siRNAs are most often packaged into carriers for systemic delivery as their negative charge and size prevent cellular penetration. Uncomplexed siRNAs that are delivered systemically are also readily cleared by the kidney and excreted. The array of carriers is vast, and excellent summaries of their chemical make-up and biological properties can be found elsewhere<sup>42–45</sup>. Among the most common are lipid-based carriers or cholesterol conjugates to the sense strand of the duplex. Cholesterol-conjugated siRNAs, which are commercially available, enable improved uptake to the liver as they are bound by low-density lipoprotein (LDL) in serum and LDL uptake in the liver is robust<sup>46</sup>. Lipophilic siRNAs can also bind high-density lipoprotein (HDL); this can target siRNAs to tissues with HDL receptors, such as gut<sup>47</sup>, kidney<sup>47</sup> and vaginal<sup>48</sup> epithelial cells and oligodendrocytes in the brain<sup>49</sup>.

Exciting data in nonhuman primates showed that a single delivery of siRNAs complexed into stable nucleic acid lipid particles (SNALPs) reduced target gene expression for almost 2 weeks<sup>50</sup>. Recently the same delivery strategy was used successfully to protect nonhuman primates from a lethal challenge of Ebola virus, using siRNAs targeting the expression of three Ebola virus proteins<sup>51</sup>. Improvements in SNALPs that reduce the doses required for effective silencing in nonhuman primates by ~tenfold will augment the clinical utility of these reagents<sup>40</sup>.

Complexing siRNAs with carriers also provides opportunities for targeting specific cells or, in the case of cancer, tumour beds. In the first in-human study, nanoparticles designed for enhanced uptake to cancer cells by using transferrin-receptor-targeting ligands showed reduced levels of the target mRNA and evidence for

Table 2 | **Methods for the delivery of RNAi triggers to cells and tissues**

Species/formulation	Packaging capacity	Applications and considerations	Refs*
<b>Viral vector</b>			
Adenovirus	Up to ~35 kb, usually <10 kb	dsDNA vector with large packaging capacity, transient expression, highly immunogenic	76,77
Adeno-associated virus (AAV)	~4.5 kb	ssDNA vector, small packaging capacity, mildly immunogenic, lasting expression in nondividing cells, capsid pseudotyping/engineering facilitates specific cell-targeting	82,91, 103,108
Lentivirus	Up to 13.5 kb (larger inserts will decrease titre)	RNA vector, integration competent and incompetent forms available, less immunogenic than adenovirus or AAV, envelope pseudotyping facilitates cell targeting, clinical production more difficult than for adenovirus or AAV	83-88, 140,155
Herpes simplex virus	150 kb	DNA vector, episomal, lasting expression, immunogenic	119
<b>Bacterial vector species<sup>‡</sup></b>			
<i>Escherichia coli</i> , <i>S. Typhimurium</i> <sup>§</sup>		Delivery of short hairpin RNA or small interfering RNA to gut tissue	73-75
<b>Non-viral formulations<sup>  </sup></b>			
Nanoparticle		Self-assembling, may target specific receptors, requires technical expertise to prepare	59
Stable nucleic acid lipid particle (SNALP)		Stable for systemic delivery, broad cell-type delivery	51
Aptamer		Targeting of specific receptors, requires sophisticated screening to develop	53
Cholesterol		Stable for systemic delivery, broad cell-type delivery	46

\*Representative references. <sup>‡</sup>Bacterial minicells can carry plasmids, short interfering RNAs or drugs. <sup>§</sup>*Salmonella enterica* subsp. *enterica* serovar Typhimurium. <sup>||</sup>The nucleic acids in non-viral carriers can be any size from small oligonucleotides to large artificial chromosomes.

siRNA-mediated cleavage of that target<sup>52</sup>. As the study continues, it will be interesting to learn the pharmacokinetics of the siRNAs in additional patients and to see the clinical effects of the therapy. Other carriers for tissue-specific targeting include aptamers<sup>53,54</sup>, antibodies<sup>55-58</sup>, peptides and proteins<sup>52,59</sup>, and oligonucleotide agonists<sup>36</sup>. Some are synthetically linked to the siRNAs, as in the case of oligonucleotides, peptides and aptamers, whereas others are part of more complex carrier systems (reviewed in REFS 42,60).

**Expression systems for RNAi triggers**


**shRNAs and artificial miRNAs.** Expression of shRNAs or artificial miRNAs is achieved by delivering plasmids or by using bacterial or viral vectors. These RNAi triggers are transcribed as sense and antisense sequences connected by a loop of unpaired nucleotides to mimic pre-miRNAs (for shRNAs) or pri-miRNAs (for artificial miRNAs). Following transcription, artificial miRNAs are processed by the Drosha-DGCR8 complex and exported to the cytoplasm, where they engage the pre-RISC complex via the normal miRNA biogenesis pathway (FIG. 1). After cleavage of the passenger (non-guide) strand, the guide strand directs RISC to the mRNA target.

Although the goal for shRNAs is to make a pre-miRNA mimic, shRNA transcripts often do not reflect Drosha cleavage products<sup>61,62</sup>. If they do not contain the typical 3' dinucleotide overhang, transport by exportin 5 will be impaired. Reduced shRNA export

could cause nuclear accumulation and toxicity<sup>63,64</sup>. Alternatively, if exportin 5 recognizes the duplexes but shRNA expression is exceptionally high relative to endogenous miRNAs, exportin 5 can become saturated. Overexpression of exportin 5 can alleviate the blockage, but saturation of downstream processing pathways can occur. One method to alleviate saturation of exportin 5 and Argonaute proteins is to overexpress them concomitantly with shRNAs<sup>65</sup>. However, for therapeutic purposes it might be more appropriate to use weaker promoters<sup>61,66</sup> or artificial miRNAs<sup>64,67-70</sup>. As miRNA hairpins can be embedded in larger transcripts, the artificial miRNA approach is more suited than shRNAs to RNA polymerase II-based expression systems that provide tissue-specific and inducible gene silencing. The products of RNAi expression systems need to be assessed carefully to ascertain whether the desired strand is loaded into RISC and how well the RNAs are expressed and processed (FIG. 2).

**Delivery systems: non-viral vectors.** RNAi trigger-expressing plasmids can be packaged into many of the same carriers that can be used for siRNA delivery, although the nature of the particle will change with the different cargo (large DNAs versus small RNAs). Several non-viral platforms for gene delivery are being investigated (reviewed in REF. 71) and, as for siRNAs, commercial reagents are available for plasmid transfection of cell lines and some primary cells *in vitro*.





**Figure 2 | Workflow for testing therapeutic RNAi triggers. a** | Cartoon depicting a luciferase reporter system that is used to confirm that the appropriate strand of small interfering RNAs (siRNAs) or stem–loop platforms from RNAi expression systems is loaded into the RNA-induced silencing complex (RISC). A plasmid with a luciferase reporter that harbours sequences complementary to the guide strand in the 3' UTR is cotransfected with the RNAi system, and if the appropriate guide strand is loaded, luciferase activity will diminish. When a reporter that contains sequences complementary to the passenger strand is cotransfected, luciferase activity should not be reduced. Because silencing is based on a microRNA (miRNA)-like mechanism, inhibition of luciferase activity will indicate RISC loading, independent of the sequence's ability to induce target cleavage. **b** | Northern blot analysis can be used to evaluate RNAi triggers expressed from vectors. If the short hairpin RNA (shRNA) or primary miRNA (pri-miRNA) mimics are poorly processed but expressed efficiently, build-up of shRNAs may occur (lane 1). Appropriate processing should yield readily detectable mature, processed siRNAs with minimal levels of unprocessed material (lane 2). Northern blots with probes for the passenger strand can also be used to assess RISC loading of the unintended strand (not shown). **c** | Small RNA quantitative PCR to quantify the mature product will yield information about overall levels of mature product, which is important to know to understand dosing. The figure shows an example of results obtained from effectively or poorly processed RNA precursors. Cloning and sequencing of the mature small RNAs can be used to assess the silencing RNAs in more detail (not shown). Ct, threshold cycle.

**Minicells**

Bacteria-derived cells that have no chromosomes and are non-living. They can be loaded with drugs, plasmids or small interfering RNAs.

**Adeno-associated virus (AAV).**

A member of the genus *Dependovirus*. These viruses have small, ssDNA genomes and are not known to cause disease in humans. AAVs are commonly used as recombinant vectors in gene therapy applications.

**Episome**

A dsDNA segment that can persist independently of chromosomal DNA.

**Capsid**

The outer protein coat of a virus, such as adeno-associated virus or adenovirus.

Bacteria can be used as an innovative platform for RNAi delivery; this approach is built on earlier work showing that therapeutic bacteria can enter tumours in patients with cancer<sup>72</sup>, presumably via a permissive vasculature. The basic premise is that recombinantly engineered *Escherichia coli* can enter mammalian cells after *in vivo* delivery and transfer shRNAs. When bacteria containing plasmids that expressed shRNAs targeting  $\beta$ -catenin were fed to mice,  $\beta$ -catenin expression was reduced in the intestinal epithelium<sup>73</sup>. This platform is now in clinical testing for familial adenomatous polyposis, an inherited form of colon cancer<sup>74</sup>. A related approach in mice used minicells derived from *Salmonella enterica* subsp. *enterica* serovar Typhimurium and targeted them to tumour-cell-surface receptors to deliver siRNAs or shRNAs; this method reduced tumour burden and improved mouse survival<sup>75</sup>.

**Delivery systems: viral vectors.** The viral vectors used to deliver shRNAs or artificial miRNAs include murine

oncoretroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAVs), and herpesviruses, among others (TABLE 2). We refer the reader to recent reviews describing the biology and production of these vector systems<sup>76–80</sup>. Here we highlight major differences among some of the tools that are relevant to their use for RNAi-based applications, with respect to their tissue tropisms and the fate of their recombinant genomes in host cells.

The genomes of recombinant adenoviruses and AAVs generally remain episomal after the virus has entered the host cell, the viral capsid has been uncoated and the nucleocapsid has been transported to the cell nucleus. An advantage of vector systems with genomes that remain episomal is that insertional mutagenesis is avoided. However, unless only transient expression is desired, their use is limited to cells that divide slowly (for example, some epithelial cells) or not at all (for example, neurons) because the episomal genome will be lost following cell divisions. Naturally occurring differences in capsid structures among adenoviruses or

Box 1 | **Off-target silencing**

When designing therapeutic strategies involving small interfering RNAs (siRNAs) or expression-based systems, it is important to know details about the RNA strand that is incorporated into the RNA-induced silencing complex (RISC) and mediates silencing. Genomically encoded microRNAs (miRNAs) in mammalian cells possess the necessary information within the miRNA duplex for appropriate loading of the miRNA or the miRNA\* strand. So, when using chemically synthesized siRNAs or systems that express short hairpin RNAs or artificial miRNAs, the design must take into account what nature has taught us. For example, the designer should consider whether the artificial miRNA has the 5' and 3' ends that are necessary for appropriate processing and export, and whether subsequent biochemical processing results in loading of the correct strand into RISC.

There are several methods to determine which strand is loaded into RISC, including northern blots, small RNA PCRs and luciferase-based plasmid systems with targets for the guide strand or the passenger strand placed in the 3' UTR of the reporter (FIG. 2). Although there are publicly available algorithms that use thermodynamic rules in silencing RNA, it is important to sequence expressed constructs to characterize their termini. Sequencing is necessary to ascertain the relative proportions of the intended mature silencing RNA and RNAs that result when cleavage sites are shifted by one or several nucleotides; such alterations to the RNA could substantially increase off-target silencing. Off-target silencing occurs through the interaction of a seed sequence with transcripts harbouring complementary sequences<sup>147–151</sup>. siRNAs with high off-target potentials, based on seed complement frequencies in the transcriptome, result in increased silencing of unintended mRNAs and toxicity<sup>152</sup>. This problem can be reduced by designs that bias RISC loading towards the correct RNA strand and that ensure that processing of silencing RNA precursors only produces the desired small RNA duplex. Incorporating chemical modifications, such as 2'-O-methyl groups, into the guide and passenger strands of chemically synthesized siRNAs reduces indiscriminate effects of ssRNAs and dsRNAs<sup>153</sup>. Additionally, incorporation of unlocked nucleic acids (acyclic RNA mimics)<sup>154</sup> makes the RNAs poor ligands for Toll-like receptors.

Varying amounts of off-target silencing can occur with different silencing platforms because the levels of the silencing RNAs will vary. For example, for expression systems, transfection with plasmids or transduction with adenoviruses or adeno-associated viruses will yield more copies per cell than transduction with lentiviruses. siRNA transfection can also result in abundant off-target silencing if the siRNA has low on-target potency and a moderate or high off-target potential (see above). Less off-target silencing with a lentivirus-based system compared with siRNAs was reported recently, but that study used high doses of siRNAs with high off-target potential<sup>155</sup>.

**miRNA\***

The precursor microRNA (pre-miRNA) processed by Dicer generates a miRNA duplex containing the miRNA strand and the miRNA\* strand, one of which is loaded into the RNA-induced silencing complex (RISC). The ratio of one strand to the other being loaded into RISC to mediate silencing activity can vary among species, tissues, and disease or developmental settings.

**Off-target effects**

Any detectable phenotypic change that is triggered by the RNAi treatment, other than those that are derived directly or indirectly from silencing the targeted mRNA.

among AAVs affect the ability of the viruses to infect diverse cell types *in vitro* or specific cells within tissues. Capsid genes can also be manipulated to artificially alter tropism to a cell surface molecule or tissue of choice<sup>81,82</sup>. Such capsid retargeting takes advantage of the fact that once binding is established, viruses can use secondary receptors for internalization.

A major difference between adenoviruses and AAVs is their packaging capacity (~4.5 kb for AAVs compared with up to 35 kb (although usually less than 10 kb) for adenoviruses). Another distinguishing point is that all viral genes are removed from AAV vector genomes, whereas recombinant adenoviruses often express many viral genes that may induce immune responses to transduced cells and cause their subsequent elimination. For these reasons, AAVs are generally useful for achieving RNAi in cells that one wants to save, whereas adenoviruses are useful tools for either transient expression or when immune induction is desired. Notably, both adenoviruses and AAVs infect cells at multiple copies per cell, which can be problematic with shRNAs (instead of

artificial miRNAs), as dosing may be amplified. Dosing is a function of the copy number and how efficiently the hairpin is expressed and processed<sup>62</sup> and, in many cases, higher expression is not necessarily beneficial. If hairpins are inappropriately processed, or expressed at very high levels, toxicity (BOX 1) and/or saturation of the RNAi machinery can occur<sup>63,64</sup> (see above).

Lentiviruses are another delivery option. If their RNA genomes contain hairpins, they can be cleaved by RNA processing enzymes, which can be a problem during vector production. However, the negative effect this has on vector titres can be rescued by inhibiting the RNAi pathway<sup>83</sup>. Expression cassette placement is also important for lentiviruses expressing shRNAs or artificial miRNAs, as some configurations negatively affect vector production or shRNA expression<sup>84–86</sup>. Recombinant lentiviruses can transduce dividing and non-dividing cells and generally integrate into transcriptionally active chromatin. A potential problem is that insertion could activate an oncogene or inactivate a tumour suppressor gene. Insertional promiscuity can be dramatically reduced by using integrase-defective lentiviruses<sup>87</sup>. Like adenoviruses and AAVs, the vector tropism of lentiviruses can be altered, in this case through manipulation of the viral envelope used in vector production<sup>88</sup>.

The most obvious application for recombinant lentiviruses is for transduction *in vitro* or, in the case of clinical applications, *ex vivo* gene transfer to haematopoietic progenitor cells or peripheral blood lymphocytes for treatment of viral infections<sup>89</sup>. In these settings, recombinant lentiviruses are applied to cells at 1 to 5 vectors per cell, because higher concentrations are often toxic. The final number of integrants per cell is approximately 0.5 to 1 copy per cell. This fact is important when considering lentiviruses for RNAi delivery; if the copy number is low, shRNA expression from strong promoters may be preferred.

**Therapeutic applications of RNAi *in vivo***

Important considerations for therapeutic RNAi are that gene silencing approaches rarely remove 100% of a transcript, that off-target silencing can occur (BOX 1) and that each target organ, cell type and target transcript presents unique challenges. In some cases, the goal is to target every cell in an organ, in other instances promiscuous cell tropism is disadvantageous. For example, one might wish to target cancer cells for gene silencing but avoid normal surrounding tissue, or to express the therapeutic RNA in hepatocytes but not Küppfer cells after delivery to the liver. Tissue specificity can be achieved in some cases by incorporating ligands on the carrier that direct transfection or infection to the desired cell, as described above. Alternatively, researchers have taken advantage of the natural tropism<sup>90,91</sup> or modified tropism of viral vectors for cell and tissue targeting<sup>82</sup>, or have used cell-specific promoters to express the silencing RNAs.

**Delivery to the respiratory tract.** Alterations in gene expression in epithelial cells of the respiratory tract contribute to disease pathogenesis in many disorders

including asthma, chronic obstructive airway disease and cystic fibrosis. In addition, these cells are a key site of interaction between the host and the environment and many common viral pathogens replicate in these cells as the initial step in their life cycle, providing opportunities to silence viral gene products or host genes that modify the viral life cycle or the host's response to that virus. These reasons, and the fact that the respiratory tract is an accessible tissue, make the airway epithelium an attractive tissue for exploring RNAi therapies.

The potential of RNAi-based treatments to modify the host response to respiratory virus infections has been extensively studied. In 2004 and 2005 several high-profile papers were published in which synthesized siRNAs or expressed shRNAs were used to inhibit the influenza A virus<sup>92,93</sup>, severe acute respiratory syndrome (SARS) coronavirus<sup>94</sup>, respiratory syncytial virus<sup>4,94</sup> and parainfluenza virus in animal models<sup>4</sup>. These studies showed both the promise and potential pitfalls of RNAi as a therapeutic strategy. Although the respiratory tract is readily accessible using topical or aerosol delivery techniques available in the clinic, several years of basic and clinical studies in the field of gene therapy have humbled investigators. These studies used a number of well-conceived viral and non-viral delivery techniques to treat monogenetic disorders such as cystic fibrosis, but the treatments were hindered by the physical barriers posed by the epithelial cells themselves, in addition to their secretions and host defence mechanisms<sup>95,96</sup>. In principle, delivery of RNAi oligonucleotides might pose a less significant challenge than expression plasmids or other genetic payloads as oligonucleotides need only enter the cytoplasm of surface cells to function. In addition, the mucosal surface of the airways and alveoli are active sites of innate and adaptive immunity, and RNAi delivery vectors or RNAi oligonucleotides may elicit immunologic responses. In the context of anti-infection RNAi strategies, immunostimulation confounded the early preclinical results<sup>5,6,32</sup>, and possibly the ongoing clinical data<sup>97</sup>.

In addition to targeting the gene products of respiratory viruses, several groups have used siRNA technology to knock down expression of host gene products or reporter genes in the respiratory tract in animal models. To date, the animal studies have shown little efficacy<sup>95</sup> and poor delivery has also been demonstrated *in vitro* when fully differentiated cell models were studied. In short, effective RNAi activity requires the application of siRNAs before the development of a well-differentiated epithelial barrier<sup>96</sup>. Thus, efficient delivery remains an important hurdle to overcome as clinical studies are developed.

**Antiviral strategies in other tissues.** HIV remains an attractive target for drug development, including for therapies based on RNAi<sup>89</sup>. Examples of strategies include targeting the receptor for the virus and the virus itself<sup>55,98</sup>. However, the error-prone replication cycles of HIV can be problematic. Combinatorial approaches that include RNAi and other gene silencing approaches have therefore been developed for HIV.

An approach undergoing clinical testing uses lentiviral vectors expressing an shRNA targeting an exon shared by HIV *tat* and *rev* genes (the *tat/rev* common exon), combined with two HIV-specific RNA-based inhibitors (a nucleolar-localizing TAR RNA decoy and a C-C chemokine receptor type 5 (CCR5)-targeting hammerhead ribozyme)<sup>99</sup>. The strategy is to transduce haematopoietic progenitor cells *ex vivo* and then reinfuse them into patients<sup>99</sup>. Early data from this Phase I trial show that transduced cells successfully engrafted within 11 days in all four patients treated. Importantly, there were no treatment-related toxicities. Vector expression was documented for up to 24 months in multiple cell lineages, as was expression of the introduced ribozyme and shRNA.

RNAi was recently used to inhibit lethal infection by the filovirus Ebola in a primate model<sup>51</sup>. A combination of modified siRNAs targeting Ebola L polymerase, viral protein 24 (VP24) and VP35 were SNALP-formulated and delivered intravenously. This strategy protected animals from death, including those that received siRNAs only after the onset of the infection. RNAi-based therapies are also under development for hepatitis B virus (HBV)<sup>39,100</sup> and hepatitis C virus (HCV)<sup>101</sup>. As chronic hepatitis contributes significantly to hepatocellular carcinoma pathogenesis, this further drives interest in new HBV and HCV therapies as a means to reduce disease burden. As with HIV, the hepatitis viruses have a high mutation frequency during viral replication. Therefore, most current antiviral strategies focus on the delivery or expression of more than one RNAi construct to achieve success against chronic hepatitis infection<sup>101,102</sup>. A current focus of several laboratories is to use miRNA or shRNA expression methods to target more than one viral transcript<sup>103,104</sup>. Host proteins can also be targeted, for example siRNAs directed to diacylglycerol acyltransferase 1 (DGAT1) can reduce HCV virion production<sup>105</sup>. Additionally, inhibiting the expression of the host gene product polo-like kinase 1 (PLK1) using siRNA reduces HCV replication<sup>106</sup>. PLK1 inhibition is also being used in anticancer studies (see below).

Promising results have also been reported using RNAi to modify virus and host gene expression in a mouse model of genital tract herpes simplex virus 2 (HSV-2) infections<sup>48,107</sup>. Lipid-complexed RNA oligonucleotides inhibited expression of the HSV-2 *UL27* and *UL29* genes and the host receptor nectin 1 (also known as PVRL1). These approaches showed efficacy in both the prevention and treatment of infection<sup>48,107</sup>. The manipulation of host miRNAs to inhibit viral expression is also being explored (see further discussion below).

**RNAi for neurological disorders.** The blood-brain barrier limits access to the central nervous system (CNS) and thus the most practical manner to silence targets in neural cells is through direct injection of the RNAi trigger. As siRNAs have a short half-life, redosing using indwelling catheters would be required for chronic diseases. However, for acute illnesses or delivery to brain tumours, the short half-life of siRNAs may be desirable. By contrast, viral platforms provide lasting expression

**Küppfer cell**  
A macrophage-like cell that is resident in the liver and is involved in antigen presentation.



and may be ideal for chronic disorders. For example, vectors expressing therapeutic RNAi improved disease phenotypes for many months in preclinical studies in rodent models of polyglutamine repeat diseases<sup>108–113</sup>, amyotrophic lateral sclerosis<sup>114–116</sup>, Parkinson's disease<sup>117</sup> and Alzheimer's disease<sup>118,119</sup>. In nonhuman primate brains, viral-vector-based systems are safe<sup>120</sup> and, given the encouraging results of AAVs in the human brain and eye<sup>121</sup>, clinical trials for neurodegenerative diseases with AAVs expressing RNAi triggers are anticipated.

An issue to consider is the delivery to the correct cell type in the brain. Specificity for neurons versus glia has not been achieved for uncomplexed siRNAs, and in fact it has been reported that siRNAs delivered into nonhuman primate brains enter oligodendrocytes<sup>49</sup>. This might be a suitable method for therapies aimed at treating multiple sclerosis or other white matter diseases. For encapsidated viral vectors, the nature of the protein coat imparts a natural tropism for neurons (in the case of AAV2, for example) or for other cell types<sup>91</sup>. For enveloped viral vectors, such as those lentiviral systems derived from HIV, the tropism is imparted by the envelope used in vector production in a process known as pseudotyping<sup>122</sup>. Also, some vectors traffic from the site of injection to other regions of the brain via neuronal connections, but others remain localized. Thus targeting is achieved collectively by the site of injection, the propensity of the virus to infect certain cell types and traffic along or within neuronal axons and neurites, and the promoter used to drive expression of the RNAi trigger.

For chronic, dominantly inherited disorders, it may be preferable to silence only the mutant allele. For some brain diseases there are highly prevalent disease-linked polymorphisms that provide opportunities for allele-specific silencing. Primary dystonia, which is caused by a common GAG deletion in torsin A (*TOR1A*), is one example<sup>123</sup>. Other disorders have several disease-linked SNPs present in most patients and these SNPs provide an opportunity for disease allele silencing. However, when targeting a SNP using RNAi, it is critical to consider the potential for off-target binding of the seed sequence in the small RNA (BOX 1), as unintended off-target silencing could abrogate any beneficial effects from leaving the wild-type allele intact. Huntington's disease is a case in point. Preclinical work in animal models shows that partial knockdown of both alleles of huntingtin is tolerated and provides clinical benefit<sup>124</sup>, yet genotyping shows that 4 to 5 SNPs in huntingtin may be present in the majority of patients with Huntington's disease<sup>125,126</sup>. Small RNAs that are specific to the SNPs may have moderately high off-target potential and therefore should be tested for their long-term tolerability *in vivo*, as should the safety of partial reductions in expression from both mutant and wild-type alleles.

**Targeting metabolic disease and hepatic cancers.** One of the first organs tested for the effectiveness of RNAi *in vivo* was the liver<sup>127,128</sup>, and RNAi-based treatments for metabolic diseases (such as hypercholesterolaemia), viral infections, cancer<sup>6</sup> and liver fibrosis (reviewed in REF. 129) are in progress. For metabolic diseases, there

are preclinical and clinical trials underway for lowering plasma LDLs using siRNAs that target the expression of apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9). In this work, the siRNAs are complexed to carriers or embedded in liposomal particles (for example, SNALPs). Data from rodents and nonhuman primates<sup>50,122</sup> show significant LDL-lowering properties and, in one of the first trials in humans, corporate news releases stated that the SNALP-formulated APOB siRNA was well tolerated at all but the highest dose. Newer formulations that show improved potency in nonhuman primates are under development.

The liver was also one of the first organs targeted in the development of RNAi-based therapies for cancer. One study used SNALPs targeting PLK1, a cell cycle protein that is crucial for the activating phosphorylation of many cell cycle proteins; inhibition of PLK1 induces cell cycle arrest and tumour cell apoptosis<sup>130</sup>. Mice with hepatic tumours treated with SNALP-formulated PLK1 siRNA showed significant improvements in survival<sup>6</sup>. In December 2010, this technology advanced to a Phase I trial in humans with liver cancer (TABLE 1).

Another hepatic cancer application is SNALPs simultaneously delivering siRNAs to kinesin spindle protein (KSP) and vascular endothelial growth factor (VEGF). KSP is required for cell division, and VEGF is required for tumour cell growth. In early 2011, sponsors of a Phase I trial using this approach reported evidence of RNAi activity in biopsied tissue<sup>131</sup>. These preliminary reports, along with the first report of RNAi activity from exogenously applied siRNA complexes<sup>52</sup>, are important milestones in the development of RNAi delivery systems as cancer therapeutics.

**miRNAs as therapeutic targets.** The identification of misregulated miRNAs in cellular transformation and maintenance of the malignant state has profound implications for cancer therapy. As with other misregulated genes, miRNAs can be targets for gene silencing approaches, whether the miRNAs are encoded in the host genome or expressed from oncogenic viruses (reviewed in REF. 132). Inhibition of oncogenic miRNAs that regulate multiple targets might switch off dozens of cancer-promoting signals. Rather than devising siRNAs to target the misregulated miRNA, researchers have developed miRNA sponges<sup>133</sup>; these provide alternative binding platforms for the miRNAs and so inhibit their ability to bind and suppress their natural targets (FIG. 1). An early example was the intravenous delivery of antagomirs, which are chemically modified RNA oligonucleotides antisense to the miRNAs<sup>134,135</sup>. In a primate model of HCV infection, oligonucleotides that sequestered miR-122 inhibited virus replication<sup>136</sup>. Plasmid- and virus-based approaches are also being used for reducing endogenous miRNA levels<sup>133,137</sup>. Typically for this approach, strong promoters drive expression of a sequence encoding several miRNA target sites downstream of a reporter. The multiple copies expressed become targets for binding of miRNAs, which are sequestered from targeting their endogenous mRNAs.

**Antagomirs**

RNA oligonucleotides that are antisense to endogenous microRNAs. They are used for inhibiting microRNA–mRNA interactions.

**Summary and future considerations**

In addition to the developments described above, there has been substantial progress in using gene silencing approaches for treating skin<sup>138</sup> and retinal diseases<sup>139,140</sup>. Like the liver and airway, these accessible tissues were early targets for preclinical testing. Exploiting the small RNA biogenesis and gene silencing pathways for heart diseases, either using siRNAs against single targets<sup>141</sup> or inhibiting the action of misregulated miRNAs<sup>142</sup>, has also yielded promising results that are approaching clinical trials.

In addition to its utility as a stand-alone strategy, RNAi may have expanded applications as an adjuvant in multipronged treatment settings. For example, targeting multidrug resistance protein 1 (MDR1; also known as ABCB1) in cancer cells may enhance the activity of chemotherapeutics<sup>143</sup>, and other host genes have been targeted for similar ends for cancer therapeutics<sup>144–146</sup>. Another RNAi adjuvant strategy is the use of dsRNA oligonucleotides as immunostimulatory agonists alongside vaccines, as in the case of a RIG1 agonist to enhance the activity of a DNA vaccine against influenza<sup>9</sup>.

RNAi therapy development should consider whether regional delivery and partial knockdown, or global delivery and complete knockdown, is required for a therapeutic result. An example of the former is directed delivery to specific regions of the brain for Parkinson's disease. By contrast, RNAi therapy for cancer may require delivery to all cancer cells. Another important issue that is yet to be resolved is dosing of the therapeutic RNAi. In the case of cancer, pharmacologists must balance the target cells'

ability to recover from the exogenously applied siRNAs or anti-miRNA treatments with the practical considerations of patient compliance for repetitive dosing. Will clinical success and eventual cure require treatment for weeks, months or years? Viral vector expression systems for RNAi can overcome this problem by providing sustained expression, but this strategy requires genomic integration of the vector if the target cells are dividing. In order to overcome the potential dangers of genomic integration, methods for integration into genomic 'safe harbours' will be important. With respect to long-term RNAi from viral vectors as therapies for genetic diseases, the question is whether regulated expression is required. To help to answer this question, it is expected that long-term studies in large animals (for example, non-human primates) will yield valuable information regarding chronic application of inhibitory RNAs from various platforms. A further consideration is that although the end points for some trials are obvious, for example lowering blood cholesterol or reducing tumour burden, sensitive and specific end points are not always clear for chronic disorders in which the tissue cannot be easily biopsied or in which biomarkers are not validated.

In slightly more than a decade, we have advanced rapidly from RNAi discovery, to understanding the molecular processes driving small RNA biogenesis and function, to developing reagents that harness the power of the RNAi pathway. Although many hurdles remain for using these technologies for therapy, exciting early clinical results show how far we have come.

- Kim, D. H. & Rossi, J. J. Strategies for silencing human disease using RNA interference. *Nature Rev. Genet.* **8**, 173–184 (2007).
- Fire, A. *et al.* Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806–811 (1998).  
**The Nobel prize winning discovery of the RNAi mechanism in worms.**
- Elbashir, S. M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. *Genes Dev.* **15**, 188–200 (2001).  
**The discovery that RNAi activity occurs through siRNAs.**
- Bitko, V., Musiyenko, A., Shulyayeva, O. & Barik, S. Inhibition of respiratory viruses by nasally administered siRNA. *Nature Med.* **11**, 50–55 (2005).
- Robbins, M. *et al.* Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. *Hum. Gene Ther.* **19**, 991–999 (2008).
- Judge, A. D. *et al.* Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. *J. Clin. Invest.* **119**, 661–673 (2009).
- Hornung, V. *et al.* Sequence-specific potent induction of IFN- $\alpha$  by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nature Med.* **11**, 263–270 (2005).
- Judge, A. D. *et al.* Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. *Nature Biotech.* **23**, 457–462 (2005).
- Luke, J. M. *et al.* Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. *J. Virol.* **85**, 1370–1383 (2011).
- Czech, B. & Hannon, G. J. Small RNA sorting: matchmaking for Argonautes. *Nature Rev. Genet.* **12**, 19–31 (2011).
- Ghildiyal, M. & Zamore, P. D. Small silencing RNAs: an expanding universe. *Nature Rev. Genet.* **10**, 94–108 (2009).
- Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. *Nature Rev. Genet.* **11**, 597–610 (2010).
- Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. & Burge, C. B. Prediction of mammalian microRNA targets. *Cell* **115**, 787–798 (2003).  
**Recognition that the seed sequence is responsible for miRNA-based silencing of the target mRNA.**
- Shin, C. *et al.* Expanding the microRNA targeting code: functional sites with centered pairing. *Mol. Cell* **38**, 789–802 (2010).
- Kiriakidou, M. *et al.* An mRNA m7G cap binding-like motif within human Ago2 represses translation. *Cell* **129**, 1141–1151 (2007).
- Chendrimada, T. P. *et al.* MicroRNA silencing through RISC recruitment of eIF6. *Nature* **447**, 823–828 (2007).
- Thermann, R. & Hentze, M. W. Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. *Nature* **447**, 875–878 (2007).
- Eulalio, A., Behm-Ansmant, I. & Izaurralde, E. P bodies: at the crossroads of post-transcriptional pathways. *Nature Rev. Mol. Cell Biol.* **8**, 9–22 (2007).
- Piao, X., Zhang, X., Wu, L. & Belasco, J. G. CCR4-NOT deadenylates mRNA associated with RNA-induced silencing complexes in human cells. *Mol. Cell Biol.* **30**, 1486–1494 (2010).
- Guo, H., Ingolia, N. T., Weissman, J. S. & Bartel, D. P. Mammalian microRNAs predominantly act to decrease target mRNA levels. *Nature* **466**, 835–840 (2010).
- Bhattacharyya, S. N., Habermacher, R., Martine, U., Closs, E. I. & Filipowicz, W. Relief of microRNA-mediated translational repression in human cells subjected to stress. *Cell* **125**, 1111–1124 (2006).
- Matranga, C., Tomari, Y., Shin, C., Bartel, D. P. & Zamore, P. D. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. *Cell* **123**, 607–620 (2005).
- Rand, T. A., Petersen, S., Du, F. & Wang, X. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. *Cell* **123**, 621–629 (2005).
- Schwarz, D. S. *et al.* Asymmetry in the assembly of the RNAi enzyme complex. *Cell* **115**, 199–208 (2003).
- Khvorova, A., Reynolds, A. & Jayasena, S. D. Functional siRNAs and miRNAs exhibit strand bias. *Cell* **115**, 209–216 (2003).
- Czech, B. *et al.* Hierarchical rules for Argonaute loading in *Drosophila*. *Mol. Cell* **36**, 445–456 (2009).
- Sakurai, K. *et al.* A role for human Dicer in pre-RISC loading of siRNAs. *Nucleic Acids Res.* **39**, 1510–1525 (2010).
- Zamore, P. D., Tuschl, T., Sharp, P. A. & Bartel, D. P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. *Cell* **101**, 25–33 (2000).
- Kim, D. H. *et al.* Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. *Nature Biotech.* **23**, 222–226 (2005).
- Siolas, D. *et al.* Synthetic shRNAs as potent RNAi triggers. *Nature Biotech.* **23**, 227–231 (2005).
- Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. *Oligonucleotides* **19**, 89–102 (2009).
- Kleinman, M. E. *et al.* Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. *Nature* **452**, 591–597 (2008).
- Cho, W. G. *et al.* Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. *Proc. Natl Acad. Sci. USA* **106**, 7137–7142 (2009).
- Tang, X. L., Sun, J. F., Wang, X. Y., Du, L. L. & Liu, P. Blocking neuropilin-2 enhances corneal allograft survival by selectively inhibiting lymphangiogenesis on vascularized beds. *Mol. Vis.* **16**, 2354–2361 (2010).
- Cubillos-Ruiz, J. R. *et al.* Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. *J. Clin. Invest.* **119**, 2231–2244 (2009).
- Kortylewski, M. *et al.* *In vivo* delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. *Nature Biotech.* **27**, 925–932 (2009).
- Brody, J. D. *et al.* *In situ* vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. *J. Clin. Oncol.* **28**, 4324–4332 (2010).
- Judge, A. D., Bola, G., Lee, A. C. & MacLachlan, I. Design of noninflammatory synthetic siRNA mediating potent gene silencing *in vivo*. *Mol. Ther.* **13**, 494–505 (2006).

39. Morrissey, D. V. *et al.* Potent and persistent *in vivo* anti-HBV activity of chemically modified siRNAs. *Nature Biotech.* **23**, 1002–1007 (2005).
40. Semple, S. C. *et al.* Rational design of cationic lipids for siRNA delivery. *Nature Biotech.* **28**, 172–176 (2010).
41. Czauderna, F. *et al.* Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. *Nucleic Acids Res.* **31**, 2705–2716 (2003).
42. Lares, M. R., Rossi, J. J. & Ouellet, D. L. RNAi and small interfering RNAs in human disease therapeutic applications. *Trends Biotechnol.* **28**, 570–579 (2010).
43. Shim, M. S. & Kwon, Y. J. Efficient and targeted delivery of siRNA *in vivo*. *FEBS J.* **277**, 4814–4827 (2010).
44. Weinstein, S. & Peer, D. RNAi nanomedicines: challenges and opportunities within the immune system. *Nanotechnology* **21**, 252001 (2010).
45. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. *Nature Rev. Drug Discov.* **8**, 129–138 (2009).
46. Soutschek, J. *et al.* Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* **432**, 173–178 (2004).
47. Wolfrum, C. *et al.* Mechanisms and optimization of *in vivo* delivery of lipophilic siRNAs. *Nature Biotech.* **25**, 1149–1157 (2007).
48. Wu, Y. *et al.* Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. *Cell Host Microbe* **5**, 84–94 (2009).
49. Chen, Q. *et al.* Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. *J. Control. Release* **144**, 227–232 (2010).
50. Zimmermann, T. S. *et al.* RNAi-mediated gene silencing in non-human primates. *Nature* **441**, 111–114 (2006).
- A demonstration of RNAi activity against metabolic targets in nonhuman primates.**
51. Geisbert, T. W. *et al.* Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. *Lancet* **375**, 1896–1905 (2010).
52. Davis, M. E. *et al.* Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. *Nature* **464**, 1067–1070 (2010).
- The first description of RNAi activity resulting from siRNA therapy in a human.**
53. Dassie, J. P. *et al.* Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. *Nature Biotech.* **27**, 839–849 (2009).
54. Zhou, J. *et al.* Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. *Nucleic Acids Res.* **37**, 3094–3109 (2009).
55. Kumar, P. *et al.* T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. *Cell* **134**, 577–586 (2008).
56. Peer, D., Park, E. J., Morishita, Y., Carman, C. V. & Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. *Science* **319**, 627–630 (2008).
57. Kim, S. S. *et al.* RNAi-mediated *CCR5* silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. *Mol. Ther.* **18**, 370–376 (2010).
58. Zheng, X. *et al.* A novel *in vivo* siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. *Blood* **113**, 2646–2654 (2009).
59. Kumar, P. *et al.* Transvascular delivery of small interfering RNA to the central nervous system. *Nature* **448**, 39–43 (2007).
60. Peer, D. Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review. *J. Control. Release* **148**, 63–68 (2010).
61. Boudreau, R. L., Martins, I. & Davidson, B. L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs *in vitro* and *in vivo*. *Mol. Ther.* **17**, 169–175 (2009).
62. Boudreau, R. L., Monteyes, A. M. & Davidson, B. L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. *RNA* **14**, 1834–1844 (2008).
63. Grimm, D. *et al.* Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature* **441**, 537–541 (2006).
64. McBride, J. L. *et al.* Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. *Proc. Natl Acad. Sci. USA* **105**, 5868–5873 (2008).
65. Grimm, D. *et al.* Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. *J. Clin. Invest.* **120**, 3106–3119 (2010).
66. Giering, J. C., Grimm, D., Storm, T. A. & Kay, M. A. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. *Mol. Ther.* **16**, 1630–1636 (2008).
67. Zeng, Y., Yi, R. & Cullen, B. R. Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. *EMBO J.* **24**, 138–148 (2005).
68. Chung, K. H. *et al.* Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. *Nucleic Acids Res.* **34**, e53 (2006).
69. Boden, D. *et al.* Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. *Nucleic Acids Res.* **32**, 1154–1158 (2004).
70. Silva, J. M. *et al.* Second-generation shRNA libraries covering the mouse and human genomes. *Nature Genet.* **37**, 1281–1288 (2005).
71. Seow, Y. & Wood, M. J. Biological gene delivery vehicles: beyond viral vectors. *Mol. Ther.* **17**, 767–777 (2009).
72. MacDiarmid, J. A. *et al.* Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. *Cancer Cell* **11**, 431–445 (2007).
73. Xiang, S., Fruehauf, J. & Li, C. J. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. *Nature Biotech.* **24**, 697–702 (2006).
74. Keates, A. C., Fruehauf, J. H., Xiang, S., Parker, P. D. & Li, C. J. Cequent Pharmaceuticals, Inc.: the biological path for RNAi therapeutics. *Pharmacogenomics* **8**, 867–871 (2007).
75. MacDiarmid, J. A. *et al.* Sequential treatment of drug-resistant tumors with targeted micelles containing siRNA or a cytotoxic drug. *Nature Biotech.* **27**, 643–651 (2009).
76. Heilbronn, R. & Weger, S. Viral vectors for gene transfer: current status of gene therapeutics. *Handb. Exp. Pharmacol.* **197**, 143–170 (2010).
77. Hall, K., Blair Zajdel, M. E. & Blair, G. E. Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. *Biochem. J.* **431**, 321–336 (2010).
78. Matrai, J., Chuah, M. K. & VandenDriessche, T. Recent advances in lentiviral vector development and applications. *Mol. Ther.* **18**, 477–490 (2010).
79. Overbaugh, J., Miller, A. D. & Eiden, M. V. Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycoposphatidylinositol-anchored and secreted proteins. *Microbiol. Mol. Biol. Rev.* **65**, 371–389 (2001).
80. Marconi, P., Argani, R., Epstein, A. L. & Manservigi, R. HSV as a vector in vaccine development and gene therapy. *Adv. Exp. Med. Biol.* **655**, 118–144 (2009).
81. Hajitou, A. *et al.* A hybrid vector for ligand-directed tumor targeting and molecular imaging. *Clin. Invest.* **125**, 385–398 (2006).
82. Chen, Y. H., Chang, M. & Davidson, B. L. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. *Nature Med.* **15**, 1215–1218 (2009).
83. Liu, Y. P. *et al.* Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. *RNA* **16**, 1328–1339 (2010).
84. Harper, S. Q. *et al.* Optimization of feline immunodeficiency virus vectors for RNA interference. *J. Virol.* **80**, 9371–9380 (2006).
85. Amendola, M. *et al.* Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. *Mol. Ther.* **17**, 1039–1052 (2009).
86. Zhang, J. & Rossi, J. J. Strategies in designing multigene expression units to downregulate HIV-1. *Methods Mol. Biol.* **623**, 123–136 (2010).
87. Lombardo, A. *et al.* Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. *Nature Biotech.* **25**, 1298–1306 (2007).
88. Anliker, B. *et al.* Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. *Nature Methods* **7**, 929–935 (2010).
89. Rossi, J. J., June, C. H. & Kohn, D. B. Genetic therapies against HIV. *Nature Biotech.* **25**, 1444–1454 (2007).
90. Stein, C. S., Martins, I. & Davidson, B. L. The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. *Mol. Ther.* **11**, 382–389 (2005).
91. Davidson, B. L. *et al.* Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. *Proc. Natl Acad. Sci. USA* **97**, 3428–3432 (2000).
92. Tompkins, S. M., Lo, C. Y., Tumpey, T. M. & Epstein, S. L. Protection against lethal influenza virus challenge by RNA interference *in vivo*. *Proc. Natl Acad. Sci. USA* **101**, 8682–8686 (2004).
93. Ge, Q. *et al.* Inhibition of influenza virus production in virus-infected mice by RNA interference. *Proc. Natl Acad. Sci. USA* **101**, 8676–8681 (2004).
94. Li, B. J. *et al.* Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. *Nature Med.* **11**, 944–951 (2005).
95. Griesenbach, U. *et al.* Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells *in vivo*. *Respir. Res.* **7**, 26 (2006).
96. Caci, E. *et al.* Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. *Am. J. Respir. Cell. Mol. Biol.* **40**, 211–216 (2009).
97. DeVincenzo, J. *et al.* A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. *Proc. Natl Acad. Sci. USA* **107**, 8800–8805 (2010).
98. Liu, Y. P. *et al.* Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. *Mol. Ther.* **17**, 1712–1723 (2009).
99. DiGiusto, D. L. *et al.* RNA-based gene therapy for HIV with lentiviral vector-modified CD34<sup>+</sup> cells in patients undergoing transplantation for AIDS-related lymphoma. *Sci. Transl. Med.* **2**, 36ra43 (2010).
100. McCaffrey, A. P. *et al.* Inhibition of hepatitis B virus in mice by RNA interference. *Nature Biotech.* **21**, 639–644 (2003).
101. Kapadia, S. B., Brideau-Andersen, A. & Chisari, F. V. Interference of hepatitis C virus RNA replication by short interfering RNAs. *Proc. Natl Acad. Sci. USA* **100**, 2014–2018 (2003).
102. Ely, A., Naidoo, T. & Arbutnot, P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. *Nucleic Acids Res.* **37**, e91 (2009).
103. Yang, X., Haurigot, V., Zhou, S., Luo, G. & Couto, L. B. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster. *Hepatology* **52**, 1877–1887 (2010).
104. Shin, D., Lee, H., Kim, S. I., Yoon, Y. & Kim, M. Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. *RNA* **15**, 898–910 (2009).
105. Herker, E. *et al.* Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. *Nature Med.* **16**, 1295–1298 (2010).
106. Chen, Y. C. *et al.* Polo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A. *J. Virol.* **84**, 7983–7993 (2010).
107. Palliser, D. *et al.* An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. *Nature* **439**, 89–94 (2006).
108. Xia, H. *et al.* RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. *Nature Med.* **10**, 816–820 (2004).
- The first demonstration of therapeutic efficacy of RNAi *in vivo* in a model of inherited disease.**
109. Harper, S. Q. *et al.* RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. *Proc. Natl Acad. Sci. USA* **102**, 5820–5825 (2005).
110. Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S. & Mandel, R. J. Intrastratial rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. *Mol. Ther.* **12**, 618–633 (2005).
111. Machida, Y. *et al.* rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. *Biochem. Biophys. Res. Commun.* **343**, 190–197 (2006).
112. Alves, S. *et al.* Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. *PLoS ONE* **3**, e3341 (2008).
113. Drouot, V. *et al.* Sustained effects of nonallele-specific Huntington silencing. *Ann. Neurol.* **65**, 276–285 (2009).
114. Ralph, G. S. *et al.* Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. *Nature Med.* **11**, 429–433 (2005).



115. Raoul, C. *et al.* Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. *Nature Med.* **11**, 423–428 (2005).
116. Saito, K., Ishizuka, A., Siomi, H. & Siomi, M. C. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in *Drosophila* cells. *PLoS Biol.* **3**, e235 (2005).
117. Sapru, M. K. *et al.* Silencing of human  $\alpha$ -synuclein *in vitro* and in rat brain using lentiviral-mediated RNAi. *Exp. Neurol.* **198**, 382–390 (2006).
118. Singer, O. *et al.* Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. *Nature Neurosci.* **8**, 1343–1349 (2005).
119. Hong, C. S., Goins, W. F., Goss, J. R., Burton, E. A. & Glorioso, J. C. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid- $\beta$  peptide *in vivo*. *Gene Ther.* **13**, 1068–1079 (2006).
120. Hadaczek, P. *et al.* Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. *Mol. Ther.* **18**, 1458–1461 (2010).
121. Mingozzi, F. & High, K. A. Therapeutic *in vivo* gene transfer for genetic disease using AAV: progress and challenges. *Nature Rev. Genet.* **12**, 341–355 (2011).
122. Frank-Kamenetsky, M. *et al.* Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. *Proc. Natl Acad. Sci. USA* **105**, 11915–11920 (2008).
123. Gonzalez-Alegre, P., Bode, N., Davidson, B. L. & Paulson, H. L. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. *J. Neurosci.* **25**, 10502–10509 (2005).
124. Boudreau, R. L. *et al.* Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. *Mol. Ther.* **17**, 1053–1063 (2009).
125. Pfister, E. L. *et al.* Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. *Curr. Biol.* **19**, 774–778 (2009).
126. Warby, S. C. *et al.* CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. *Am. J. Hum. Genet.* **84**, 351–366 (2009).
127. Xia, H., Mao, Q., Paulson, H. L. & Davidson, B. L. siRNA-mediated gene silencing *in vitro* and *in vivo*. *Nature Biotech.* **20**, 1006–1010 (2002).
- The first description of endogenous gene silencing by a viral vector expressing shRNAs.**
128. McCaffrey, A. P. *et al.* RNA interference in adult mice. *Nature* **418**, 38–39 (2002).
129. Hu, P. F. & Xie, W. F. Targeted RNA interference for hepatic fibrosis. *Expert Opin. Biol. Ther.* **9**, 1305–1312 (2009).
130. Steegmaier, M. *et al.* BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth *in vivo*. *Curr. Biol.* **17**, 316–322 (2007).
131. Alnylam Pharmaceuticals, Inc. Alnylam demonstrates RNAi in man with systemically delivered RNAi therapeutics. *Alnylam Pharmaceuticals* [online], <http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1512322&highlight> (2011).
132. Sotiropoulou, G., Pampalakis, G., Lianidou, E. & Mourelatos, Z. Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. *RNA* **15**, 1443–1461 (2009).
133. Brown, B. D. & Naldini, L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. *Nature Rev. Genet.* **10**, 578–585 (2009).
134. Pedersen, I. M. *et al.* Interferon modulation of cellular microRNAs as an antiviral mechanism. *Nature* **449**, 919–922 (2007).
135. Krutzfeldt, J. *et al.* Silencing of microRNAs *in vivo* with 'antagomirs'. *Nature* **438**, 685–689 (2005).
136. Lanford, R. E. *et al.* Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science* **327**, 198–201 (2010).
137. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. *Nature Methods* **4**, 721–726 (2007).
138. Geusens, B., Sanders, N., Prow, T., Van Gele, M. & Lambert, J. Cutaneous short-interfering RNA therapy. *Expert Opin. Drug Deliv.* **6**, 1333–1349 (2009).
139. Chadderton, N. *et al.* Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. *Mol. Ther.* **17**, 593–599 (2009).
140. Yuan, M. K., Tao, Y., Yu, W. Z., Kai, W. & Jiang, Y. R. Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization. *Mol. Vis.* **16**, 1743–1753 (2010).
141. Poller, W., Hajjar, R., Schultheiss, H. P. & Fechner, H. Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. *Cardiovasc. Res.* **86**, 353–364 (2010).
142. Small, E. M., Frost, R. J. & Olson, E. N. MicroRNAs add a new dimension to cardiovascular disease. *Circulation* **121**, 1022–1032 (2010).
143. Susa, M. *et al.* Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. *PLoS ONE* **5**, e10764 (2010).
144. Chang, J. T. *et al.* Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. *Cancer Gene Ther.* **17**, 827–836 (2010).
145. Herrmann, A. *et al.* Targeting Stat3 in the myeloid compartment drastically improves the *in vivo* antitumor functions of adoptively transferred T cells. *Cancer Res.* **70**, 7455–7464 (2010).
146. Liu, C. *et al.* Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. *J. Control. Release* **140**, 277–283 (2009).
147. Jackson, A. L. *et al.* Expression profiling reveals off-target gene regulation by RNAi. *Nature Biotech.* **21**, 635–637 (2003).
148. Jackson, A. L. *et al.* Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. *RNA* **12**, 1179–1187 (2006).
- References 147 and 148 provide experimental validation and recognition of the importance of off-target silencing.**
149. Aleman, L. M., Doench, J. & Sharp, P. A. Comparison of siRNA-induced off-target RNA and protein effects. *RNA* **13**, 385–395 (2007).
150. Burchard, J. *et al.* MicroRNA-like off-target transcript regulation by siRNAs is species specific. *RNA* **15**, 308–315 (2009).
151. Saxena, S., Jonsson, Z. O. & Dutta, A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. *J. Biol. Chem.* **278**, 44312–44319 (2003).
152. Anderson, E. M. *et al.* Experimental validation of the importance of seed complement frequency to siRNA specificity. *RNA* **14**, 853–861 (2008).
153. Jackson, A. L. *et al.* Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. *RNA* **12**, 1197–1205 (2006).
154. Bramsen, J. B. *et al.* A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. *Nucleic Acids Res.* **38**, 5761–5773 (2010).
155. Klinghoffer, R. A. *et al.* Reduced seed region-based off-target activity with lentivirus-mediated RNAi. *RNA* **16**, 879–884 (2010).
156. Borichert, G. M., Lanier, W. & Davidson, B. L. RNA polymerase III transcribes human microRNAs. *Nature Struct. Mol. Biol.* **13**, 1097–1101 (2006).
157. Monteys, A. M. *et al.* Structure and activity of putative intronic miRNA promoters. *RNA* **16**, 495–505 (2010).
158. Ozsolak, F. *et al.* Chromatin structure analyses identify miRNA promoters. *Genes Dev.* **22**, 3172–3183 (2008).
159. Lee, Y. *et al.* The nuclear RNase III Drosha initiates microRNA processing. *Nature* **425**, 415–419 (2003).
160. Gregory, R. I. *et al.* The Microprocessor complex mediates the genesis of microRNAs. *Nature* **432**, 235–240 (2004).
161. Chung, W. J. *et al.* Computational and experimental identification of mirtrons in *Drosophila melanogaster* and *Caenorhabditis elegans*. *Genome Res.* **21**, 286–300 (2010).
162. Lund, E., Guttlinger, S., Calado, A., Dahlberg, J. E. & Kutay, U. Nuclear export of microRNA precursors. *Science* **303**, 95–98 (2004).
163. Yi, R., Qin, Y., Macara, I. G. & Cullen, B. R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. *Genes Dev.* **17**, 3011–3016 (2003).
164. Provost, P. *et al.* Ribonuclease activity and RNA binding of recombinant human Dicer. *EMBO J.* **21**, 5864–5874 (2002).
165. Forstemann, K. *et al.* Normal microRNA maturation and germ-line stem cell maintenance requires Loquacious, a double-stranded RNA-binding domain protein. *PLoS Biol.* **3**, e236 (2005).
166. Bernstein, E., Caudy, A. A., Hammond, S. M. & Hannon, G. J. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* **409**, 363–366 (2001).
167. Nykanen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering RNA structure in the RNA interference pathway. *Cell* **107**, 309–321 (2001).

#### Acknowledgements

The authors thank members of the Davidson and McCray laboratories for critical feedback. Work in the authors' laboratories is supported by the Roy J. Carver Trust and the US National Institutes of Health grants HL51670, DK54759 and NS50210.

#### Competing interests statement

The authors declare [competing financial interests](#): see Web version for details.

#### FURTHER INFORMATION

Beverly L. Davidson's homepage:

<http://www.medicine.uiowa.edu/labs/davidson>

Paul B. McCray's homepage:

<http://mccraylab.genetics.uiowa.edu>

ClinicalTrials.gov: <http://clinicaltrials.gov>

ALL LINKS ARE ACTIVE IN THE ONLINE PDF